This conversation explores the intersection of biotechnology and the beauty industry, highlighting how biotech is revolutionizing the production of cosmetic ingredients. The discussion covers the slow pace of innovation in beauty, the debate between natural and synthetic ingredients, and the role of AI in discovering new active compounds. The conversation also delves into specific examples like carmine production, the business model of Debut Biotech, and the regulatory challenges faced in bringing new products to market.

2025 saw some of the giants in molecular biology leave us.  Those that made seminal discoveries in DNA science to those that put it to work in describing the underpinnings of life left an indelible mark on history, and it is fitting that we commemorate their discoveries and contributions. 

This is a throwback to episode 484, a very important correction of their episode on glyphosate. With so much controversy around this compound it is critical to keep the information correct and consistent with a 50 year body of evidence when discussing risk and benefit. Veritassium made some mistakes, so here they are corrected so that you can participate effectively in these discussions. 

This episode originally aired on December 18, 2021.  Cindy Graham was diagnosed with glioblastoma in her late 40s. She fought the disease, and ultimately donated her tissues to research to study the nature of glioblastoma and identify potential vulnerabilities that could underlie a cure. This episode first features Dr. Shiela Singh, glioblastoma expert who has performed analysis of Cindy's cells in search of a cure.  The second part is an interview with her husband, Dr. Thomas Graham. He speaks of the power of her gift, Cindy's legacy, and the hope that cures may come because of her contribution. The fund supports glioblastoma research and student scholarships to enhance the best research in search of a cure.
 
You can support the fund at www.cindysgift.com

In today's throwback to 2022, Dr. Avindra Nath of the NIH reviews research efforts in proteins expressed from human endogenous retroviruses. It is a fascinating discussion of how genome relics may be contributing to insidious human disease. 

This throwback episode to 2018 is an interview with plant breeding pioneer Dr. Maxine Thompson. 

In this episode of the Talking Biotech podcast, Dr. Kevin Folta and Dr. Zack Abbott discuss the critical role of dietary fiber in human health, the alarming statistics regarding fiber deficiency in the population, and the innovative solutions being developed by Zbiotics to address this issue. They delve into the science behind genetically engineered probiotics that can convert sugars into fiber, enhancing gut health and microbiome diversity. The conversation also touches on future possibilities for probiotic technology and its potential to solve modern health challenges.

This cross-platform podcast is shared on Science Facts and Fallacies as well as Talking Biotech.  Cameron English, Dr. Liza Lockwood and Dr. Kevin Folta discuss the comments made during a rant on the Science Facts and Fallacies podcast concerning the rigor of peer review and alledged lack of self policing in academic publishing.  They discuss several papers in the recent public eye, with an emphasis on the process, the media response, and the nuance that is used in academic publishing, review and editorial oversight.  

In this episode of the Talking Biotech podcast, Dr. Jonathan Howard discusses his experiences during the COVID-19 pandemic, the rise of disinformation, and the anti-vaccine movement. He reflects on his role as a physician at Bellevue Hospital, the impact of misinformation on public health, and the key players who have influenced the narrative surrounding vaccines and COVID-19. Dr. Howard emphasizes the need for the medical community to stand against misinformation and the importance of engaging in public discourse to restore trust in science and public health institutions.

Summary

In this episode of the Talking Biotech Podcast, Dr. Matthew Disney discusses the potential of RNA as a therapeutic target, exploring its historical context, pathogenic roles in diseases, and the challenges and innovations in drug design. The conversation delves into specific diseases like myotonic dystrophy, ALS, and various cancers, highlighting the advantages of small molecules in treatment and the future directions of RNA therapeutics.